Is this message not displayed correctly?
Please click here for the online version.
|
|
Dear Sir or Madam, The Life Science Community met again at BIONNALE two weeks ago. Over one thousand attendees discussed current developments and networked. The topics and projects discussed at BIONNALE continue to develop. One example of this is the company FaradaIC. The founder Ryan Gutermann was a finalist in the BIONNALE Speed Lecture Award in 2017. In our interview, he explains the factors that were important for the development of his company and how he wants to tap into markets with his product. How to bring innovative AI solutions for the healthcare industry to market faster in the future is the topic of the European project “Testing and Experimentation Facility for Health AI and Robotics” (TEF-Health). In the interview, the coordination team explains the role of data security, infrastructure and certification and why this project with a budget of more than 60 million euros and 51 partners from nine countries is managed from Berlin. Noble Prize winner Emmanuelle Charpentier also agrees that the German capital city region is generally a good location for scientific networking in the current Braincity interview. The next opportunity to meet us is at BIO in Boston (5 - 8 June 2023), where HealthCapital is exhibiting at the German Pavilion. On 5 June, we’re holding a business breakfast “Business Opportunities in Berlin”. Feel free to take a look! Your Dr. Kai Uwe Bindseil Berlin Partner for Business and Technology |
|
"Be prepared to learn
new things constantly" Ryan Guterman is from Canada and obtained his PhD in chemistry from the University of Western Ontario before moving to Germany in 2015. He soon after became Group Leader at the Max Planck Institute of Colloids and Interfaces before starting his company FaradaIC Sensors GmbH in 2021. His research focus revolved around the invention of new electrolyte materials and their application in electrochemical devices. Now as CEO of FaradaIC Sensors, his goal is to create the world's first O2 gas sensor on a microchip specifically designed for mass-market applications. |
|
|
“Ultimately, the goal is to
bring health-innovations
Made in Europe to the
marketplace.” Technological advances in AI and robotics have been unprecedented and have captured the imagination of companies, start-ups and researchers alike. The new EU-funded project “Testing and Experimentation Facility for Health AI and Robotics” (TEF-Health), with a total budget of around €60 million, aims to facilitate and accelerate the validation and certification of AI and robotics in medical devices. In the #ai_berlin interview with project lead Prof. Dr. Petra Ritter, Director of the Berlin Institute of Health (BIH) and the Brain Simulation Section at the Department of Neurology with Experimental Neurology at Charité and project partner Dr. Dirk Schlesinger Head of the TÜV AI Lab we learned more about their innovative approach, the importance of data accessibility and being at the heart of Berlin's AI landscape. |
|
|
"Basic research is the
basis for innovation" For her groundbreaking work at the molecular mechanisms of a bacterial immune system, called CRISPR/Cas9, and its repurpose into a tool for genome editing, Prof. Dr. Emmanuelle Charpentier won the nobel prize in chemistry in 2020, together with Jennifer Doudna from the University of California, Berkeley, USA. In 2018 she founded the independent Max Planck Unit for the Science of Pathogens (MPUSP) to strengthen fundamental research on pathogens causing diseases in humans. In the Brain City interview, she tells us about her goals, her current research, advantages of Berlin as a science location and her love of sports and culture. |
|
|
The tip from our
relocation experts
Relocating to a new city can be tricky, both from a business as from a private perspective.
|
|
|
Our Talent Services team has put together a great landing page with an overview on the main aspects to consider when arriving and living in Berlin, such as visa, health insurance, learning German, housing, international day cares/ schools, etc. And also from a business perspective we have you covered: Our business location center offers a series of HOW TO Session videos on topics such as setting up a business in Berlin, Berlin public funding overview, etc. And then you can always contact us relocation managers for more details and further questions. Looking forward to getting in touch and assisting you in setting up your business in Berlin. Flavia Kruse Berlin Partner for Business and Technology MedTech | Healthcare | Digital Health 📧 |
|
|
|
BIO International
Convention
June 5-8, 2023 | Boston, USA
Read more
|
|
|
HIMSS Europe
June 7-9, 2023 | Lisbon, Portugal European Health Conference & Exhibition Read more |
|
Systems Biology of Human Disease (SBHD) conference
June 19-21, 2023 | Berlin, Germany The SBHD conference series is a binational annual event initially launched by Peter Sorger and colleagues at Harvard Medical School in 2008 with its location alternating between the USA and Germany. SBHD 2023 will take place in Berlin, Germany, hosted by BIH at Charité – Universitätsmedizin Berlin. Read more |
|
Current Topics in
Bioinformatics 2023
June 26, 2023 | Berlin, Germany
Best Practices in Health Data Management and Advances in Digital Health
Read more
|
|
|
MPS World Summit 2023
June 26-30, 2023 | Berlin, Germany Microphysiological systems (MPS) comprise a number of bioengineering breakthroughs that reproduce organ architecture and function in vitro. Fueled by stem-cell technologies, a broad variety of especially human models and test systems have emerged, which make relevant experimental tools broadly available through international and multidisciplinary collaborations. Read more |
|
For more events in the life science region Berlin-Brandenburg click here. |
|
Ariceum Therapeutics Announces Extension of Series A Financing to EUR 47.75M to Advance its Next Generation Radiopharmaceutical Clinical Pipeline
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces the successful completion of a Series A extension financing, raising a further EUR 22.75 million, following the EUR 25 million Series A financing announced in June 2022. Read more |
|
FDA Approval for BIOTRONIK’s
Prospera™ Spinal Cord
Stimulation System
|
|
|
Global Leader in Cardiac Rhythm Technology Solutions Expands Therapies for the Treatment of Chronic Intractable Pain with a New Approach to Managing Spinal Cord Stimulation Read more |
|
3B Pharmaceuticals from Berlin announced licensing agreement with Novartis Innovative Therapies
3B Pharmaceuticals GmbH (3BP), a private German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications, announced that it has entered into an amended and restated licensing agreement with Novartis Innovative Therapies AG (Novartis) for 3BP's FAP-targeting peptide technology. Read more |
|
ProBioGen and ImmunOs Therapeutics team up to deliver innovative therapy for cancer patients
Read more |
|
Glycotope presents glyco-engineered cell lines at the 2023 American Association for Cancer Research (AACR) meeting
Read more |
|
Cellphenomics’ and Kyan Therapeutics combined platforms provide best-in-class solutions to support the biopharma industry
Read more |
|
Eckert & Ziegler receives manufacturing authorization for GMP-grade Lutetium-177
Read more |
|
DX Technology demonstrates high detection accuracy for atrial fibrillation in single-chamber ICD patients
Read more |
|
LabTwin & PerkinElmer Informatics partner for real-time data capture
Read more |
|
International research team with Charité and Max Planck Institute for Molecular Genetics discover that protein droplets may cause many types of genetic disease
Malfunction of cellular condensates is a disease mechanism relevant for congenital malformations, common diseases, and cancer Read more
|
|
Max Delbrück Center discovers how non-coding parts of the genome drive evolution Genes are not the only drivers of evolution. The iconic fins of skates are caused by changes in the non-coding parts of the genome and its three-dimensional structure, a research team including Darío Lupiáñez at the Max Delbrück Center reports in “Nature”.
|
|
|
Scientists from the Berlin Institute of Health have discovered that autoantibodies in Covid-19 patients are likely not to blame when patients become severely ill
Critically ill COVID-19 patients often have antibodies in their blood that bind to the body’s own structures, so-called autoantibodies. Scientists from the BIH at Charité and the Max Delbrück Center have now discovered that these autoantibodies frequently bind to not just one but multiple targets. Read more |
|
An international team led by Charité – Universitätsmedizin Berlin has constructed the largest cellular proteomic map to date, using yeasts as model organisms
Read more |
|
Max Delbrück Center reveals the harmful effects of immune cells in hypertension
Read more |
|
Berlin Institute of Health at Charité (BIH) have demonstrated that human progenitor cells can regenerate large bone defects and form new mineralized tissue
Read more |
|
Nasal vaccine, developed by researchers from Berlin, to prevent COVID-19 passes first tests
Read more |
|
Max Delbrück Center has successfully generated genetically defined mouse models for two subtypes of multiple myeloma
Read more |
|
TechnologyAndCooperationOffers
|
|
|
Novel broad spectrum SARS-CoV-2 Vaccine Gene
Read more |
|
Safer Sleeping Beauty transposase variants with improved integration profiles (away from exons)
Read more |
|
Invention enables the production of albicidine, which could form the basis for novel, highly effective and bacteria-resistant antibiotics
Read more |
|
Activity-enhanced variant of hyeractive Sleeping Beauty transposase SB100X
Read more |
|
For more news from the cluster healthcare industries click here. |
|
EDITOR | IMPRINT
This newsletter is operated by the Cluster Management Healthcare Industries Berlin-Brandenburg HealthCapital.
Berlin Partner for Business and Technology GmbH
Fasanenstrasse 85 | 10623 Berlin
Phone +49 30 46302-270
E-Mail: info (at) healthcapital.de
Commercial Registry Entry
Entered in the commercial registry of the Charlottenburg District Court,
Registration number: HRB 13072 B
VAT ID: DE 136629780
CEO: Dr. Stefan Franzke
Chairman of the Supervisory Board: Carsten Jung
© 2023 Berlin Partner for Business and Technology GmbH |
|
The newsletter of the Cluster healthcare industries Berlin-Brandenburg is a project of Berlin Partner for Business and Technology.
|
|
|
You have been forwarded this newsletter and would like to subscribe?
Please click here.You want to unsubscribe from the newsletter (to: unknown@noemail.com)? Please click here.
|
|
|
|
|
